Advanced BioDesign

What Advanced BioDesign does

Advanced BioDesign is a French clinical-stage biotechnology company, founded in 2010 and headquartered in Saint Priest, France, that develops small-molecule inhibitors targeting Aldehyde Dehydrogenase 1 (ALDH1), an enzyme implicated in cancer cell metabolism, immunomodulation, and tumor chemoresistance. The company's stated mission is to treat patients facing chemotherapy-resistant cancers with elevated ALDH1 levels, with indicated indications spanning acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), melanoma, and other ALDH1-high tumors.

The pipeline is anchored by ABD-3001, a first-in-class small-molecule ALDH inhibitor that entered clinical trials in early 2023 for AML, with initial results described as showing a good safety profile. A second-generation candidate, ABD-0171, is in preclinical development for solid tumors and is positioned for combination use with anti-PD1 checkpoint inhibitors based on reported preclinical synergy data. The portfolio is complemented by ALDESCREEN®, an in-house predictive and prognostic companion diagnostic intended to stratify patients by ALDH1 expression and select candidates for ALDH1 inhibitor therapy, effectively coupling drug and diagnostic development into an integrated offering.

Commercially, Advanced BioDesign is pre-revenue and is following a traditional pharmaceutical development and commercialization pathway. Future revenue is intended to come from prescription and hospital-channel sales of approved ALDH1 inhibitors and from sales of the ALDESCREEN® test, with distribution to be established upon regulatory approval (no commercial distribution partners are disclosed). The company employs 11–50 staff, is privately held, and has been financed primarily by the life-sciences investor Xerys across disclosed rounds in 2013, 2020 (~$9.8 million), and 2023 (~$15.6 million). Leadership comprises co-founder, CEO and Chairman Ismail Ceylan, COO Guillaume Martin, CSO Mileidys Perez Alea, and Head of Engineering Studies Andrada Constantinescu.

Name

Advanced BioDesign

Legal name

Advanced BioDesign

Website

https://a-biodesign.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Advanced BioDesign is a French clinical-stage biotechnology company developing first-in-class small-molecule ALDH1 inhibitors, led by ABD-3001 in AML trials, alongside a second-generation solid-tumor candidate ABD-0171 and the ALDESCREEN® companion diagnostic, targeting chemotherapy-resistant cancers.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Oncology drug development
• Small molecule inhibitors
• Companion diagnostics
• Cancer therapeutics
• Clinical-stage biotechnology

Headquarters

HQ city

Saint Priest

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical stage biotechnology company. Revenue will be generated through commercialization of ALDH1 inhibitor drugs (ABD-3001, ABD-0171) and diagnostic tests (ALDESCREEN®) upon regulatory approval. Expected to follow traditional pharmaceutical commercialization model via prescription and hospital sales channels.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Advanced BioDesign is a clinical-stage biotechnology company developing first-in-class small-molecule inhibitors of ALDH1 enzymes to overcome tumor drug resistance in oncology. Its lead candidate ABD-3001 entered clinical trials in early 2023 for acute myeloid leukemia, with a second-generation inhibitor ABD-0171 in preclinical development for solid tumors in combination with anti-PD1 therapy. The portfolio is supported by ALDESCREEN®, a proprietary predictive and prognostic companion diagnostic that stratifies patients based on ALDH1 expression.

Product overview

Advanced BioDesign is a clinical-stage biotechnology company developing a pipeline of ALDH1 inhibitors aimed at overcoming tumor drug resistance in oncology. The company's core product is ABD-3001, a first-in-class small-molecule inhibitor of ALDH enzymes in clinical development for blood and solid tumors. The second-generation inhibitor ABD-0171 targets solid tumors with enhanced efficacy in combination with anti-PD1 therapy. The portfolio is supported by ALDESCREEN®, a companion diagnostic test that identifies and stratifies patients based on ALDH1 expression levels.

Differentiator

Problem solved

Functional benefit

Brands

• ALDESCREEN®: Predictive and prognostic test to identify and stratify patients with elevated ALDH1 levels.

Products and services

• ABD-3001 First-in-class small-molecule inhibitor of the ALDH family of enzymes in clinical development for acute myeloid leukemia, non-small cell lung cancer, melanoma, and other cancers with elevated ALDH1 levels.
• ABD-0171 Second-generation ALDH inhibitor developed for solid tumors with a potentiated effect in combination with anti-PD1 checkpoint immunotherapy, supported by preclinical efficacy data.
• ALDESCREEN® Predictive and prognostic in vitro diagnostic test that identifies and stratifies patients with elevated ALDH1 levels to determine eligibility for ALDH1 inhibitor therapy, supporting personalized treatment selection.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• GlycoMimetics: Clinical-stage US biotech developing targeted therapies for hematologic malignancies including AML. Comparable to Advanced BioDesign in stage, AML focus, and small-molecule/biological approach to oncology resistance.
• Aprea Therapeutics: Clinical-stage biotech developing small-molecule reactivators of p53 for AML and other cancers. Directly comparable as a small-cap, clinical-stage company addressing AML with a novel targeted mechanism.
• Celyad Oncology: Belgian clinical-stage biotech developing engineered cell therapies and small molecules for hematologic and solid tumors. Comparable in geography, stage, and oncology focus area.
• Kura Oncology: Clinical-stage precision oncology biotech with pipeline assets for AML and solid tumors. Comparable as a small-cap, clinical-stage targeted oncology developer using biomarker-driven patient selection.

Broad incumbents

• Astellas Pharma: Global Japanese pharmaceutical company with a substantial oncology and AML portfolio (including Xospata for AML). Comparable as a broad incumbent with overlapping hematology/AML drug development activity.
• Servier: Leading French independent pharmaceutical group with growing oncology portfolio. Comparable as the dominant French pharma incumbent and a potential regional partner or acquirer for Advanced BioDesign's assets.
• Ipsen: Major French-based specialty pharmaceutical company with oncology products including cabozantinib-related assets and an active hematology business. Comparable as a French incumbent in oncology with acquisition/partnership interest in clinical-stage biotechs.
• Roche: Global pharmaceutical leader with a dominant AML/NSCLC franchise (incl. Hemlibra, Tarceva, Tecentriq) and active checkpoint-inhibitor portfolio, making it a likely partner or comparator for ABD-0171 combination strategies.

Emerging players

• Molecular Partners: Swiss clinical-stage biotech developing DARPin-based oncology therapeutics. Comparable as a small European clinical-stage biotech with targeted oncology candidates at similar funding scale.
• Bio-Path Holdings: Clinical-stage biotech developing DNA-directed RNAi therapeutics for AML and other oncology indications. Comparable in clinical-stage status, AML/solid tumor focus, and small-cap targeted oncology positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/abiodesign
• YouTubeyoutube.com/@advancedbiodesign3217
• LinkedInlinkedin.com/company/advanced-biodesign

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advanced BioDesign